CommercialCoverageMedium impact
Expanded coverage for Arexvy, an adjuvanted respiratory syncytial virus (RSV) vaccine for Commercial Members (Retroactively effective 03/11/2026)
Independence Blue Cross·Family Medicine, Internal Medicine, Pediatrics +2 more·News & Announcements
Effective date
Mar 11, 2026
We identified it
Jun 19, 2026
Summary
Expanded coverage for Arexvy RSV vaccine is now available for commercial members, with coverage retroactively effective from March 11, 2026. This means previously denied claims for this vaccine can be resubmitted and new claims should be processed under the expanded coverage guidelines.
Action Required
Immediately: Billing team should identify any previously denied Arexvy RSV vaccine claims from March 11, 2026 onward and resubmit them for commercial members. Update billing software to reflect expanded coverage for Arexvy vaccine under commercial plans. Verify vaccine administration codes are being billed correctly for future Arexvy claims.